Recombinant Borrelia Bavarriens 58 produced in E.coli is a non-glycosylated, polypeptide chain having a calculated molecular mass of 61kDa.
Borrelia Bavarriensis 58 is expressed with a -6x His tag at N-terminus and purified by proprietary chromatographic techniques.
B. bavariensis is one of several pathogenic species within the B. burgdorferi sensu lato complex, alongside B. burgdorferi sensu stricto, B. afzelii, B. garinii, B. spielmanii, and B. mayonii . Previously considered a subtype of B. garinii (OspA serotype 4 or NT29-like), B. bavariensis was proposed as a separate genospecies in 2009 and validated in 2013 .
This species demonstrates several distinctive characteristics:
It shows a high propensity to infect humans and is associated with severe manifestations of Lyme borreliosis, particularly neuroborreliosis
It is distributed across Eurasia, utilizing either Ixodes ricinus (Europe) or Ixodes persulcatus (Asia) as vectors
Despite causing significant human disease, it is rarely recovered from field-collected Ixodes ticks
Molecular clock analyses estimate that:
The split between B. garinii and B. bavariensis occurred approximately 137,000 generations ago
The divergence between the two B. bavariensis populations (European and Asian) happened more recently, around 92,000 generations ago
These estimates are based on a mutation rate of 10^-7 substitutions per site per generation, though it's important to note this rate has not been definitively proven for B. burgdorferi sensu lato .
B. bavariensis genomes combine a high degree of genetic conservation with significant plasticity:
All isolates share the main chromosome and five plasmids
Beyond these conserved elements, the repertoire of other plasmids is highly variable
Genome modification mechanisms include plasmid losses, gains through horizontal transfer, and plasmid fusions
European and Asian populations show distinct patterns:
European isolates exhibit limited diversity in genome content with some geographic structure
Asian isolates each possess unique plasmid repertoires without obvious geographic differentiation between Japanese and Russian isolates
Plasmid identification in B. burgdorferi sensu lato genomes can be facilitated by identifying plasmid partition genes on assembled contigs. Specifically:
Five such genes have been described in B. burgdorferi sensu stricto
Each replicon typically contains only one copy of these genes unless it represents a fusion of two plasmids
The PFam32 protein family sequences are commonly used to name plasmids based on homology to B. burgdorferi sensu stricto
Not all plasmids possess PFam32, but PFam50 and 57/62 also appear unique for each plasmid type and can aid identification in such cases
For accurate plasmid reconstruction:
A combination of long-read (Pacific Bioscience) and short-read (Illumina) sequencing techniques allows proper genome reconstruction in most cases
When only short-read sequencing data is available, a very close reference is necessary for accurate assembly
B. bavariensis, like other Lyme disease spirochetes, must overcome the first line of defense of the innate immune system after transmission to mammalian hosts. This is accomplished through two primary mechanisms:
Specifically in B. bavariensis, the proteins BGA66 and BGA71 (members of the PFam54 family) inhibit complement activation by:
Interacting with the late complement components C7, C8, and C9
Two B. bavariensis strains, PBN and PNi, naturally lack the entire PFam54 gene array while maintaining over 95% genomic identity to the reference strain PBi . This natural occurrence presents unique research opportunities:
These strains serve as natural knockouts, circumventing the technical hurdles of simultaneously deleting all PFam54 proteins
Comparative studies reveal that PBN and PNi show reduced survival in human serum compared to PBi
Complementation experiments demonstrate that introducing recombinant BGA66 and BGA71 restores serum resistance
Each recombinant protein individually confers serum resistance, while their combination does not enhance protection further
The properties of these strains are summarized in the following table:
Isolate | Genospecies | Year of culturing | Country | Biological origin | Disease manifestation | lp54 length (kb) |
---|---|---|---|---|---|---|
PBi | Borrelia bavariensis | <1993 | Germany | Human | Neuroborreliosis | 60.4 |
PBN | Borrelia bavariensis | 1999 | Germany | Human | Neuroborreliosis | 46.6 |
PNi | Borrelia bavariensis | 2000 | Germany | Human | Lymphoma | 46.6 |
BALB/c mice have been successfully used to study B. bavariensis infection dynamics. Key methodological considerations include:
Intradermal inoculation of spirochetes (with culture medium as a control)
Assessment of spirochete burden at 21 days post-inoculation
Tissue sampling should include the inoculation site, heart, bladder, ear, knee joints, and tibiotarsal joints
Quantitative analysis of spirochete burden in these tissues provides insights into strain-specific tissue tropism
In comparative studies using this model, PFam54-containing (PBi) and PFam54-deficient strains (PBN and PNi) all established productive infections in mice, suggesting that:
PFam54 is not essential for spirochete persistence in mice after intradermal infection
Absence of PFam54 may lead to strain-specific differences in the efficiency of colonizing certain murine tissues
To confirm the absence of PFam54 genes, researchers should employ multiple complementary approaches:
Genomic sequencing using both long-read (PacBio) and short-read (Illumina) technologies
Paralog-specific PCR using primers designed for individual PFam54 genes
Verification of PCR products through Sanger sequencing to confirm identity
Comparative analysis of lp54 plasmid length (typically shorter in PFam54-deficient strains)
When unexpected PCR products are observed, sequencing is essential to determine whether they represent PFam54 genes or unrelated genomic regions, as was noted when primers targeting bga68 amplified a chromosomal region in PFam54-deficient strains .
The crystal structure of BGA71, a potent MAC inhibitor, has been determined at 2.9 Å resolution, revealing:
A cysteine cross-linked homodimer structure
Based on this structure and sequence alignment with CspA from B. burgdorferi, potential binding sites for C7 and C9 (MAC constituents) have been proposed
These structural insights:
Illuminate the molecular mechanisms of immune evasion developed by pathogenic Borrelia species
Aid understanding of Lyme disease pathogenesis
May facilitate development of new strategies to prevent Lyme disease
Comparative genetic diversity analysis shows specific patterns across Borrelia species:
Species | Diversity π | Tajima's D |
---|---|---|
All samples (111) | 0.045 (0.011) | −0.13 (0.40) |
B. garinii (26) | 0.007 (0.003) | −0.48 (0.59) |
B. bavariensis (29) | 0.008 (0,004) | −0.60 (0.72) |
B. burgdorferi s.s.(22) | 0.004 (0.003) | −1.21 (0.65) |
B. afzelii (16) | 0.002 (0.001) | −0.42 (0.85) |
These statistics suggest:
B. bavariensis shows intermediate levels of diversity (π = 0.008) compared to other Borrelia species
The negative Tajima's D value (-0.60) suggests potential population expansion or purifying selection
Certain genes show evidence of balancing selection across Borrelia species, including the cytidine deaminase gene cdd (BB0618), which displays high diversity and elevated Tajima's D in both B. garinii and B. bavariensis
Understanding these patterns may help identify genes under selection that could be important during speciation events or population divergence.
Borrelia bavariensis is a species of bacteria belonging to the genus Borrelia, which is part of the spirochete phylum. This genus is known for causing borreliosis, a zoonotic, vector-borne disease transmitted primarily by ticks and, in some cases, by lice. Among the 36 known species of Borrelia, 12 are known to cause Lyme disease or borreliosis, with major species including Borrelia burgdorferi, Borrelia afzelii, Borrelia garinii, and Borrelia valaisiana .
The p58 protein is a significant antigen associated with Borrelia bavariensis. It plays a crucial role in the bacterium’s ability to infect and persist within its host. The p58 protein is often targeted in diagnostic assays and research studies due to its immunogenic properties.
Recombinant p58 protein from Borrelia bavariensis is produced using recombinant DNA technology. This involves cloning the gene encoding the p58 protein into an expression system, typically E. coli, to produce the protein in large quantities. The recombinant protein is then purified using various chromatographic techniques to ensure high purity and functionality .
The recombinant p58 protein is typically expressed with a hexa-histidine purification tag, which facilitates its purification using nickel-affinity chromatography. The protein is stored in a buffer with neutral to slightly alkaline pH and 20% glycerol as a cryoprotective agent. It is recommended to store the protein at -70°C or below to maintain its stability and prevent degradation .